STREAMING NOW: Watch Now

Lilly to Study Use of Arthritis Drug to Treat COVID-19

Patrik Jonsson is president of Lilly Bio-Medicines (photo courtesy: Eli Lilly and Co.)

Indianapolis-based Eli Lilly and Co. is exploring whether one of its FDA-approved treatments for rheumatoid arthritis (RA) could be used to treat patients with COVID-19.

Posted: Apr 13, 2020 2:45 PM

INDIANAPOLIS (Inside INdiana Business) - Indianapolis-based Eli Lilly and Co. (NYSE: LLY) is exploring whether one of its FDA-approved treatments for rheumatoid arthritis (RA) could be used to treat patients with COVID-19.

The company has announced it will begin clinical trials this month on the drug baricitinib on patients in the U.S. who are hospitalized and diagnosed with the disease.

“Those patients have developed what is called an acute respiratory distress syndrome,” said Patrik Jonsson, president of Lilly Bio-Medicines.

The U.S. Food and Drug Administration approved the use of baricitinib, which is marketed as Olumiant, in June 2018 for the treatment of adult patients with moderately to severely active rheumatoid arthritis.

Jonsson said Lilly will collaborate with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, to examine if the anti-inflammatory benefits of baricitinib seen in RA patients could have similar efficacy in advanced cases of COVID-19 patients.

“That is the primary focus to really understand if we could provide relief for those patients who participate in it. If that could be confirmed, I think we'll probably consider different study setups as well.”

Lilly said for the NIAID study, Baricitinib will be tested on the spectrum of hospitalized patients, from mild to moderate to severe cases, including those patients being ventilated.

Jonsson said preclinical data seems to support the hypothesis that the RA treatment could work. To validate the success, the NIAID-Lilly study will utilize a placebo-controlled study.

“We have just made the commitment to do whatever we can through our scientific forces, overcome and combat the coronavirus. But it's amazing all of the initiatives that have been announced just over the last couple of weeks. So now, making this partnership with the NIAID, it's really exciting for us,” Jonsson said.

For Jonsson, this endeavor is not only about a scientific process. There is also a very personal connection. Prior to his current role at the company headquarters in Indianapolis, Jonsson oversaw Lilly’s central and southern European operations, including Italy and Spain

Jonsson lived in Italy for six years. In a country of 60 million people, nearly 20,000 have died from COVID-19. Spain has registered approximately 18,000 deaths, among its population of 46 million.

“I’m in almost daily contact with my friends both in Italy and in Spain,” said Jonsson. “Whoever I'm talking to back there, they have someone that they are close to that is either severely ill or even having passed away as a result of this virus.”

Just last week, Jonsson spoke with former colleagues in Spain about the pandemic’s impact. “He said, ‘Patrik, please take this serious(ly), take it serious(ly) because this is really, really a devastating situation.”

He said the discovery of the possible use of the drug on COVID-19 patients stemmed from research conducted in February in London.

“They used an artificial intelligence model to try to check in the literature…if there was a medicine already in a marketplace approved for something different, not for COVID-19,” explained Jonsson. But the U.K. researchers said their A.I. outcomes indicated baricitinib might have not only an antiviral impact but also an anti-inflammatory effect on COVID-19 patients.

“This NIAID study presents an important opportunity to test whether baricitinib can help these patients,” said Dr. Vincent Marconi, professor of medicine and global health at Emory University School of Medicine. “There is an urgent need for new strategies to help hospitalized COVID-19 patients, many of whom will progress to respiratory failure.”

Lilly said testing will begin in the U.S. and it expects results within the next two months. Testing could also be expanded to locations in Europe and Asia.

The company said the medication is currently approved for use in over 65 countries, including the U.S.

Terre Haute
Partly Cloudy
64° wxIcon
Hi: 65° Lo: 47°
Feels Like: 64°
Robinson
Partly Cloudy
61° wxIcon
Hi: 63° Lo: 46°
Feels Like: 61°
Indianapolis
Partly Cloudy
61° wxIcon
Hi: 61° Lo: 47°
Feels Like: 61°
Rockville
Partly Cloudy
62° wxIcon
Hi: 66° Lo: 46°
Feels Like: 62°
Casey
Clear
63° wxIcon
Hi: 62° Lo: 46°
Feels Like: 63°
Brazil
Partly Cloudy
64° wxIcon
Hi: 65° Lo: 46°
Feels Like: 64°
Marshall
Partly Cloudy
64° wxIcon
Hi: 64° Lo: 44°
Feels Like: 64°
More Clouds Overnight
WTHI Planner
WTHI Temps
WTHI Radar

WTHI Events

 

Illinois Coronavirus Cases

(Widget updates once daily at 7 p.m. CT)

Cases: 1343875

Reported Deaths: 24410
CountyCasesDeaths
Cook5380959996
DuPage893431270
Will74435981
Lake66368977
Kane57580768
Winnebago32526469
Madison30250518
McHenry28156284
St. Clair27650510
Peoria22686297
Champaign20373144
Sangamon18437233
McLean17818175
Tazewell16675277
Rock Island14720306
Kankakee13954207
Kendall1282791
LaSalle12286239
Macon10575194
DeKalb9728119
Vermilion9366131
Adams8345120
Williamson7340128
Whiteside7100166
Boone661671
Ogle601480
Grundy579771
Clinton574190
Coles564494
Knox5484139
Jackson495663
Henry487963
Livingston475184
Effingham470672
Stephenson466881
Macoupin466081
Woodford465474
Marion4447115
Franklin439872
Monroe434791
Jefferson4232119
Randolph411984
Lee410552
Morgan384180
Fulton382251
Logan381657
Montgomery368773
Bureau365882
Christian362073
Fayette315855
Perry314159
Iroquois296465
McDonough276345
Jersey268349
Douglas257435
Saline255153
Lawrence239925
Shelby227737
Union224240
Crawford210826
Bond201924
Cass197524
Jo Daviess179824
Pike178451
Clark178032
Warren177846
Wayne175852
Ford175446
Hancock174231
Richland173640
Carroll173536
White168726
Edgar168339
Washington163525
Moultrie159726
Clay148243
Mason147944
Piatt145814
De Witt145424
Mercer143833
Greene143233
Johnson141214
Wabash134212
Massac132940
Cumberland128819
Menard121512
Jasper114818
Marshall103218
Hamilton82915
Schuyler7305
Brown6996
Pulaski6837
Stark63023
Edwards56712
Henderson52214
Calhoun5152
Scott4761
Putnam4733
Alexander46511
Gallatin4574
Hardin38312
Pope3144
Out of IL70
Unassigned02344

Indiana Coronavirus Cases

(Widget updates once daily at 8 p.m. ET)

Cases: 724214

Reported Deaths: 13363
CountyCasesDeaths
Marion989071736
Lake53172962
Allen40223675
Hamilton35354408
St. Joseph35270550
Elkhart28228437
Tippecanoe22297217
Vanderburgh22231396
Porter18560304
Johnson17832376
Hendricks17098313
Clark12897191
Madison12519339
Vigo12379244
Monroe11811168
LaPorte11691210
Delaware10571185
Howard9823215
Kosciusko9347117
Hancock8204139
Bartholomew8036155
Warrick7754155
Floyd7630176
Wayne7002198
Grant6986174
Boone6652101
Morgan6529139
Dubois6139117
Marshall5954111
Dearborn577177
Cass5769105
Henry5671102
Noble555783
Jackson499672
Shelby488196
Lawrence4470120
Gibson433791
Harrison432972
Clinton426353
DeKalb423284
Montgomery423088
Whitley392739
Huntington386380
Steuben381057
Miami379165
Knox370990
Jasper361347
Putnam357760
Wabash352478
Adams340354
Ripley338370
Jefferson328481
White312254
Daviess294399
Wells290281
Decatur282992
Fayette278362
Greene276085
Posey270733
Scott264453
LaGrange263870
Clay258945
Randolph239581
Washington239131
Spencer230431
Jennings228848
Starke213252
Fountain211846
Sullivan210442
Owen195856
Fulton194240
Jay190429
Carroll187820
Perry182537
Orange181854
Rush172625
Vermillion167643
Franklin167235
Tipton161945
Parke145416
Blackford134332
Pike132634
Pulaski115945
Newton106734
Brown101441
Crawford99014
Benton98114
Martin87415
Warren80515
Switzerland7808
Union70610
Ohio56211
Unassigned0413